Transitioning to WHODrug Global?

Are you currently a user of WHODrug Enhanced or WHODrug Enhanced and WHODrug Herbal? Please view our recommendations and download our WHODrug Global Transition plan below for more practical information regarding your transition.

UMC recommends the following:

New studies, starting after 1st March, 2017, should use WHODrug Global once accessed by the user. For new studies starting after 15th March, 2019, the use of WHODrug Global is required by U.S. FDA.

For ongoing studies that are regularly upversioned and are planned to end before 2020, the sponsor and CRO should decide together whether to upgrade to WHODrug Global or not.

Ongoing studies that are regularly upversioned and are planned to end after 2020, should be upgraded to WHODrug Global at your convenience.

It is acceptable for studies that are not upgraded to stay on the same version, but we recommend ensuring that it complies with regulatory expectations.

Documents

Read more about WHODrug

Last modified on: January 16, 2018
.